Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
Identifieur interne : 001D22 ( Main/Exploration ); précédent : 001D21; suivant : 001D23Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
Auteurs : Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-07-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- Akathisia, Drug-Induced (drug therapy), Akathisia, Drug-Induced (etiology), Animals, Antagonism, Antiparkinson Agents (adverse effects), Behavior, Animal (drug effects), Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Dyskinesia, Famotidine, Famotidine (therapeutic use), Female, H2 Histamine receptor, Histamine, Histamine H2 Antagonists (therapeutic use), Levodopa, Levodopa (adverse effects), MPTP, MPTP Poisoning (drug therapy), Macaca fascicularis, Male, Models, Monkey, Nervous system diseases, Parkinson disease, Parkinson's disease, Time Factors, dyskinesia, famotidine, histamine.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- drug effects : Behavior, Animal.
- drug therapy : Akathisia, Drug-Induced, MPTP Poisoning.
- etiology : Akathisia, Drug-Induced.
- chemical , therapeutic use : Famotidine, Histamine H2 Antagonists.
- Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Female, Macaca fascicularis, Male, Time Factors.
Abstract
Levodopa‐induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H2 antagonist, famotidine (1, 3, and 30 mg/kg) to treat levodopa‐induced dyskinesia and wearing off in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐macaque model of PD. Famotidine (3 mg/kg) increased peak activity, enhanced peak anti‐parkinsonian action (1 and 3 mg/kg), and extended duration of action (3 mg/kg, by 38%) of a low dose of levodopa (compared to low dose levodopa alone). Enhancement of anti‐parkinsonian actions of low dose levodopa by famotidine (3 mg/kg) was associated with only mild, nondisabling dystonia. Famotidine had no effect on the anti‐parkinsonian actions of high dose levodopa (compared to high dose levodopa alone). However, famotidine (1, 3, and 30 mg/kg) had a significant effect on chorea, but not dystonia, induced by high dose levodopa (compared to high dose levodopa alone). Famotidine increased high dose levodopa–induced “good quality” on time, i.e., on time not associated with disabling dyskinesia, by up to 28% (compared to high dose levodopa alone). In conclusion, famotidine, a drug currently available for use in the clinic, can enhance the peak‐dose anti‐parkinsonian actions and extend total duration of action of a low dose of levodopa, without producing disabling dyskinesia. Furthermore, in combination with a higher dose of levodopa, famotidine can reduce peak‐dose levodopa‐induced chorea and improve the quality of on‐time. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23069
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000059
- to stream Istex, to step Curation: 000059
- to stream Istex, to step Checkpoint: 000A01
- to stream PubMed, to step Corpus: 001874
- to stream PubMed, to step Curation: 001874
- to stream PubMed, to step Checkpoint: 001914
- to stream Ncbi, to step Merge: 002B28
- to stream Ncbi, to step Curation: 002B28
- to stream Ncbi, to step Checkpoint: 002B28
- to stream Main, to step Merge: 002158
- to stream PascalFrancis, to step Corpus: 000992
- to stream PascalFrancis, to step Curation: 002327
- to stream PascalFrancis, to step Checkpoint: 000A88
- to stream Main, to step Merge: 002675
- to stream Main, to step Curation: 001D22
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease</title><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Van Der Meij, Anne" sort="Van Der Meij, Anne" uniqKey="Van Der Meij A" first="Anne" last="Van Der Meij">Anne Van Der Meij</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BE8D332BF3526939D657D6225C69569BB9433C84</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23069</idno><idno type="url">https://api.istex.fr/document/BE8D332BF3526939D657D6225C69569BB9433C84/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000059</idno><idno type="wicri:Area/Istex/Curation">000059</idno><idno type="wicri:Area/Istex/Checkpoint">000A01</idno><idno type="wicri:doubleKey">0885-3185:2010:Johnston T:effect:of:histamine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20310030</idno><idno type="wicri:Area/PubMed/Corpus">001874</idno><idno type="wicri:Area/PubMed/Curation">001874</idno><idno type="wicri:Area/PubMed/Checkpoint">001914</idno><idno type="wicri:Area/Ncbi/Merge">002B28</idno><idno type="wicri:Area/Ncbi/Curation">002B28</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B28</idno><idno type="wicri:Area/Main/Merge">002158</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0377346</idno><idno type="wicri:Area/PascalFrancis/Corpus">000992</idno><idno type="wicri:Area/PascalFrancis/Curation">002327</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000A88</idno><idno type="wicri:doubleKey">0885-3185:2010:Johnston T:effect:of:histamine</idno><idno type="wicri:Area/Main/Merge">002675</idno><idno type="wicri:Area/Main/Curation">001D22</idno><idno type="wicri:Area/Main/Exploration">001D22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease</title><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Van Der Meij, Anne" sort="Van Der Meij, Anne" uniqKey="Van Der Meij A" first="Anne" last="Van Der Meij">Anne Van Der Meij</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Academic Medical Centre, University of Amsterdam</wicri:regionArea><wicri:noRegion>University of Amsterdam</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-30">2010-07-30</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1379">1379</biblScope><biblScope unit="page" to="1390">1390</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BE8D332BF3526939D657D6225C69569BB9433C84</idno><idno type="DOI">10.1002/mds.23069</idno><idno type="ArticleID">MDS23069</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Akathisia, Drug-Induced (drug therapy)</term><term>Akathisia, Drug-Induced (etiology)</term><term>Animals</term><term>Antagonism</term><term>Antiparkinson Agents (adverse effects)</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Interactions</term><term>Dyskinesia</term><term>Famotidine</term><term>Famotidine (therapeutic use)</term><term>Female</term><term>H2 Histamine receptor</term><term>Histamine</term><term>Histamine H2 Antagonists (therapeutic use)</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>MPTP</term><term>MPTP Poisoning (drug therapy)</term><term>Macaca fascicularis</term><term>Male</term><term>Models</term><term>Monkey</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Time Factors</term><term>dyskinesia</term><term>famotidine</term><term>histamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Akathisia, Drug-Induced</term><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Famotidine</term><term>Histamine H2 Antagonists</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Interactions</term><term>Female</term><term>Macaca fascicularis</term><term>Male</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagonisme</term><term>Dyskinésie</term><term>Famotidine</term><term>Histamine</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Modèle</term><term>Pathologie du système nerveux</term><term>Récepteur histaminergique H2</term><term>Singe</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these problems. Here, we asses the ability of the clinically available, selective histamine H2 antagonist, famotidine (1, 3, and 30 mg/kg) to treat levodopa‐induced dyskinesia and wearing off in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐macaque model of PD. Famotidine (3 mg/kg) increased peak activity, enhanced peak anti‐parkinsonian action (1 and 3 mg/kg), and extended duration of action (3 mg/kg, by 38%) of a low dose of levodopa (compared to low dose levodopa alone). Enhancement of anti‐parkinsonian actions of low dose levodopa by famotidine (3 mg/kg) was associated with only mild, nondisabling dystonia. Famotidine had no effect on the anti‐parkinsonian actions of high dose levodopa (compared to high dose levodopa alone). However, famotidine (1, 3, and 30 mg/kg) had a significant effect on chorea, but not dystonia, induced by high dose levodopa (compared to high dose levodopa alone). Famotidine increased high dose levodopa–induced “good quality” on time, i.e., on time not associated with disabling dyskinesia, by up to 28% (compared to high dose levodopa alone). In conclusion, famotidine, a drug currently available for use in the clinic, can enhance the peak‐dose anti‐parkinsonian actions and extend total duration of action of a low dose of levodopa, without producing disabling dyskinesia. Furthermore, in combination with a higher dose of levodopa, famotidine can reduce peak‐dose levodopa‐induced chorea and improve the quality of on‐time. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>Pays-Bas</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></country><country name="Pays-Bas"><noRegion><name sortKey="Van Der Meij, Anne" sort="Van Der Meij, Anne" uniqKey="Van Der Meij A" first="Anne" last="Van Der Meij">Anne Van Der Meij</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BE8D332BF3526939D657D6225C69569BB9433C84
|texte= Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |